Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 12, 2006, Pages 633-640

  Cefali, E A ^a,c   Simmons, P D ^a   Stanek, E J ^a   Shamp, T R ^b  

^a Kos Pharmaceuticals Inc   (United States)

^b Prism Research   (United States)

^c Kos Pharmaceuticals Inc   (United States)

Author keywords

Flushing; Formulation; Niacin

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; FEVER; FILM COATING; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RIGOR; SCALP; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PRURITUS; SKIN REDNESS; SKIN TINGLING; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; VOLUNTEER;

EID: 33845413306     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44633     Document Type: Article

References (11)

1. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998; 82: 74U-81U.
2. Cefali EA, Bova D, Inventors. Kos Pharmaceuticals, Inc., Intermediate-release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles. US patent. 2002; 6,406,715 B1.
3. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231: 360-381.
4. Data on file. A single-dose, crossover study of the pharmacokinetics and urinary excretion of niacin and its major metabolites from Niaspan in reference to an immediate-release formulation. Report to Protocol 91/18, Kos Pharmaceuticals, Inc. 1994, January 11.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
6. Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998; 82: 737-743.
7. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998; 47: 1097-1104.
8. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994; 271: 672-677.
9. Pieper JA. Understanding niacin formulations. Am J Manag Care. 2002; 8 (Suppl): 5308-5314.
10. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000; 86 (Suppl): 35L-40L.
11. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep. 2001; 3: 74-82.